<p>根据 SWS Partners 最近向证券交易委员会（SEC）提交的 13F 文件，该公司在 2023 年第三季度增持了 Natera, Inc.（NASDAQ:NTRA - 免费报告）11.8% 的股份。该公司在本季度购买了 4,980 股后，持有该医疗研究公司 47,037 股股票。Natera 占 SWS Partners 投资组合的 1.8%，是其第 12 大持股。截至最近的 SEC 文件，SWS Partners 在 Natera 的持股价值为 7,572,000 美元。</p>
<ul>
<li>3 家不为人知的医疗保健公司</li>
</ul>
<p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Blue Trust Inc.在第三季度增持了 Natera 23.1% 的股份。Blue Trust Inc.目前持有 431 股该医疗研究公司的股票，价值 69,000 美元，此前在该期间内又购买了 81 股。CWM LLC 在第三季度增持了 Natera 的股份 72.2%。CWM LLC 目前持有 70,925 股该医疗研究公司的股票，价值 11,417,000 美元，此前在上个季度又购买了 29,740 股。Swedbank AB 在第三季度增持了 Natera 的股份 7.3%。Swedbank AB 目前持有 45,170 股该医疗研究公司的股票，价值 7,271,000 美元，此前在上个季度又购买了 3,090 股。Vontobel Holding Ltd.在第三季度增持了 Natera 的股份 192.5%。Vontobel Holding Ltd.目前持有 8,531 股该医疗研究公司的股票，价值 1,373,000 美元，此前在该期间内又购买了 5,614 股。最后，Yousif Capital Management LLC 在第三季度增持了 Natera 4.5% 的股份。Yousif Capital Management LLC 目前持有 1,682 股该医疗研究公司的股票，价值 271,000 美元，此前在上个季度又购买了 72 股。机构投资者和对冲基金持有该公司 99.90% 的股份。</p>
<h2>分析师评级变动</h2>
<p>多家券商对 NTRA 发布了报告。法国巴黎银行将 Natera 的股票评级上调至 “持有”，并在 10 月 27 日的报告中设定了 172.00 美元的目标价。BTIG Research 在 12 月 5 日的研究报告中将 Natera 的目标价从 230.00 美元上调至 260.00 美元，并给予该公司 “买入” 评级。巴克莱在 12 月 15 日的报告中将 Natera 的目标价从 230.00 美元上调至 270.00 美元，并给予该股票 “增持” 评级。斯蒂芬斯在 11 月 13 日的报告中将 Natera 的目标价从 197.00 美元上调至 235.00 美元，并给予该公司 “增持” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Natera 股票的 “卖出（d-）” 评级。十五位分析师对该股票给予了买入评级，三位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，Natera 目前的平均评级为 “适度买入”，共识目标价为 231.18 美元。</p>
<ul>
<li>Myriad Genetics 因遗传癌症检测而股价飙升</li>
</ul>
<p><strong>查看我们最新的 Natera 股票分析</strong></p>
<h2>Natera 的内部买卖</h2>
<p>在相关消息中，内部人士 Solomon Moshkevich 于 12 月 12 日星期五出售了 4,692 股该公司的股票。该股票以 230.76 美元的平均价格出售，总交易额为 1,082,725.92 美元。出售后，该内部人士在公司中持有 113,065 股，价值约为 26,090,879.40 美元。此交易代表其持股减少了 3.98%。该出售在向证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，首席执行官 Steven Leonard Chapman 于 12 月 1 日星期一出售了 4,400 股 Natera 股票。该股票以 238.07 美元的平均价格出售，总交易额为 1,047,508.00 美元。出售完成后，首席执行官直接持有 140,416 股该公司的股票，价值 33,428,837.12 美元。该交易使其持股减少了 3.04%。有关此出售的更多详细信息可在官方 SEC 披露中找到。在上个季度，内部人士出售了 365,164 股公司股票，价值 76,621,909 美元。公司内部人士持有该公司 5.63% 的股份。</p>
<h2>Natera 股票表现</h2>
<p>Natera 股票在周五开盘价为 233.74 美元。Natera, Inc.的 52 周低点为 125.38 美元，52 周高点为 246.90 美元。该公司的市值为 323.3 亿美元，市盈率为-102.07，贝塔值为 1.63。该股票的 50 日移动平均线为 218.14 美元，200 日移动平均线为 181.36 美元。</p>
<p>Natera（NASDAQ:NTRA - 获取免费报告）最近于 11 月 7 日发布了季度财报。该医疗研究公司报告本季度每股收益（EPS）为（0.64 美元），低于分析师共识预期的（0.39 美元）25 美分。Natera 的净利润率为-14.61%，股本回报率为-25.07%。该公司本季度的收入为 5.9218 亿美元，而分析师预期为 5.1455 亿美元。在去年同期，该公司每股收益为（0.26 美元）。该公司的收入同比增长 34.7%。分析师预计 Natera, Inc.在当前财年将发布-1.49 的每股收益。</p>
<h2>Natera 公司简介</h2>
<p>（免费报告）</p>
<p>Natera 是一家全球诊断公司，开发和商业化无细胞 DNA 及其他基因检测技术用于临床应用。该公司专注于三个主要领域：生殖健康（包括无创产前检测和携带者筛查）、肿瘤学（用于最小残留病和复发监测的肿瘤信息检测）以及器官移植（用于检测移植物损伤的无细胞 DNA 检测）。Natera 结合实验室检测、专有生物信息学和临床报告，为临床医生和患者提供个性化的基因信息。</p>
<p>主要产品包括 Panorama，一种无创产前检测，筛查胎儿染色体异常和特定单基因疾病；Horizon 携带者筛查，用于遗传性疾病；Signatera，一种个性化的肿瘤信息检测，用于检测癌症患者的最小残留病和监测治疗反应；以及 Prospera，一种供体来源的无细胞 DNA 检测，用于评估器官排斥的风险。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Natera 更好的股票</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Natera 吗？</h2>
<p>在考虑 Natera 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Natera 并不在名单上。</p>
<p>虽然 Natera 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NTRA

<p>SWS Partners 在第三季度增持了 Natera, Inc.的股份，增幅为 11.8%，目前持有 47,037 股，市值为 757 万美元。其他投资者也调整了他们的持仓。分析师的评级意见不一，普遍目标价为 231.18 美元。内部人士出售了股份，减少了他们的持股比例。Natera 的股票开盘价为 233.74 美元，市值为 323.3 亿美元</p>

<p>SWS Partners grew its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 11.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,037 shares of the medical research company's stock after buying an additional 4,980 shares during the quarter. Natera comprises 1.8% of SWS Partners' investment portfolio, making the stock its 12th biggest holding. SWS Partners' holdings in Natera were worth $7,572,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 SWS Partners 最近向证券交易委员会（SEC）提交的 13F 文件，该公司在 2023 年第三季度增持了 Natera, Inc.（NASDAQ:NTRA - 免费报告）11.8% 的股份。该公司在本季度购买了 4,980 股后，持有该医疗研究公司 47,037 股股票。Natera 占 SWS Partners 投资组合的 1.8%，是其第 12 大持股。截至最近的 SEC 文件，SWS Partners 在 Natera 的持股价值为 7,572,000 美元。</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不为人知的医疗保健公司</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in Natera by 23.1% in the third quarter. Blue Trust Inc. now owns 431 shares of the medical research company's stock valued at $69,000 after acquiring an additional 81 shares during the period. CWM LLC increased its holdings in shares of Natera by 72.2% in the 3rd quarter. CWM LLC now owns 70,925 shares of the medical research company's stock valued at $11,417,000 after purchasing an additional 29,740 shares in the last quarter. Swedbank AB increased its holdings in shares of Natera by 7.3% in the 3rd quarter. Swedbank AB now owns 45,170 shares of the medical research company's stock valued at $7,271,000 after purchasing an additional 3,090 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company's stock valued at $1,373,000 after purchasing an additional 5,614 shares during the period. Finally, Yousif Capital Management LLC boosted its holdings in Natera by 4.5% during the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company's stock worth $271,000 after buying an additional 72 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Blue Trust Inc.在第三季度增持了 Natera 23.1% 的股份。Blue Trust Inc.目前持有 431 股该医疗研究公司的股票，价值 69,000 美元，此前在该期间内又购买了 81 股。CWM LLC 在第三季度增持了 Natera 的股份 72.2%。CWM LLC 目前持有 70,925 股该医疗研究公司的股票，价值 11,417,000 美元，此前在上个季度又购买了 29,740 股。Swedbank AB 在第三季度增持了 Natera 的股份 7.3%。Swedbank AB 目前持有 45,170 股该医疗研究公司的股票，价值 7,271,000 美元，此前在上个季度又购买了 3,090 股。Vontobel Holding Ltd.在第三季度增持了 Natera 的股份 192.5%。Vontobel Holding Ltd.目前持有 8,531 股该医疗研究公司的股票，价值 1,373,000 美元，此前在该期间内又购买了 5,614 股。最后，Yousif Capital Management LLC 在第三季度增持了 Natera 4.5% 的股份。Yousif Capital Management LLC 目前持有 1,682 股该医疗研究公司的股票，价值 271,000 美元，此前在上个季度又购买了 72 股。机构投资者和对冲基金持有该公司 99.90% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages have issued reports on NTRA. BNP Paribas raised shares of Natera to a &#34;hold&#34; rating and set a $172.00 target price for the company in a report on Monday, October 27th. BTIG Research raised their price objective on Natera from $230.00 to $260.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, December 5th. Barclays lifted their price objective on Natera from $230.00 to $270.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, December 15th. Stephens upped their target price on Natera from $197.00 to $235.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Natera in a research note on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Natera currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $231.18.</p>
<div class="lb-trans"><p>多家券商对 NTRA 发布了报告。法国巴黎银行将 Natera 的股票评级上调至 “持有”，并在 10 月 27 日的报告中设定了 172.00 美元的目标价。BTIG Research 在 12 月 5 日的研究报告中将 Natera 的目标价从 230.00 美元上调至 260.00 美元，并给予该公司 “买入” 评级。巴克莱在 12 月 15 日的报告中将 Natera 的目标价从 230.00 美元上调至 270.00 美元，并给予该股票 “增持” 评级。斯蒂芬斯在 11 月 13 日的报告中将 Natera 的目标价从 197.00 美元上调至 235.00 美元，并给予该公司 “增持” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Natera 股票的 “卖出（d-）” 评级。十五位分析师对该股票给予了买入评级，三位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，Natera 目前的平均评级为 “适度买入”，共识目标价为 231.18 美元。</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 因遗传癌症检测而股价飙升</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on Natera</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Natera 股票分析</strong></p>
</div><h2>Insider Buying and Selling at Natera</h2>
<div class="lb-trans"><h2>Natera 的内部买卖</h2>
</div><p>In related news, insider Solomon Moshkevich sold 4,692 shares of the firm's stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92. Following the sale, the insider owned 113,065 shares in the company, valued at approximately $26,090,879.40. This trade represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 4,400 shares of Natera stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $238.07, for a total transaction of $1,047,508.00. Following the completion of the sale, the chief executive officer directly owned 140,416 shares of the company's stock, valued at $33,428,837.12. The trade was a 3.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 365,164 shares of company stock valued at $76,621,909. Corporate insiders own 5.63% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Solomon Moshkevich 于 12 月 12 日星期五出售了 4,692 股该公司的股票。该股票以 230.76 美元的平均价格出售，总交易额为 1,082,725.92 美元。出售后，该内部人士在公司中持有 113,065 股，价值约为 26,090,879.40 美元。此交易代表其持股减少了 3.98%。该出售在向证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，首席执行官 Steven Leonard Chapman 于 12 月 1 日星期一出售了 4,400 股 Natera 股票。该股票以 238.07 美元的平均价格出售，总交易额为 1,047,508.00 美元。出售完成后，首席执行官直接持有 140,416 股该公司的股票，价值 33,428,837.12 美元。该交易使其持股减少了 3.04%。有关此出售的更多详细信息可在官方 SEC 披露中找到。在上个季度，内部人士出售了 365,164 股公司股票，价值 76,621,909 美元。公司内部人士持有该公司 5.63% 的股份。</p>
</div><h2>Natera Stock Performance</h2>
<div class="lb-trans"><h2>Natera 股票表现</h2>
</div><p>Natera stock opened at $233.74 on Friday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $246.90. The company has a market capitalization of $32.33 billion, a price-to-earnings ratio of -102.07 and a beta of 1.63. The stock has a fifty day moving average of $218.14 and a two-hundred day moving average of $181.36.</p>
<div class="lb-trans"><p>Natera 股票在周五开盘价为 233.74 美元。Natera, Inc.的 52 周低点为 125.38 美元，52 周高点为 246.90 美元。该公司的市值为 323.3 亿美元，市盈率为-102.07，贝塔值为 1.63。该股票的 50 日移动平均线为 218.14 美元，200 日移动平均线为 181.36 美元。</p>
</div><p>Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period in the previous year, the business earned ($0.26) EPS. The firm's revenue was up 34.7% on a year-over-year basis. On average, analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Natera（NASDAQ:NTRA - 获取免费报告）最近于 11 月 7 日发布了季度财报。该医疗研究公司报告本季度每股收益（EPS）为（0.64 美元），低于分析师共识预期的（0.39 美元）25 美分。Natera 的净利润率为-14.61%，股本回报率为-25.07%。该公司本季度的收入为 5.9218 亿美元，而分析师预期为 5.1455 亿美元。在去年同期，该公司每股收益为（0.26 美元）。该公司的收入同比增长 34.7%。分析师预计 Natera, Inc.在当前财年将发布-1.49 的每股收益。</p>
</div><h2>Natera Company Profile</h2>
<div class="lb-trans"><h2>Natera 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.</p>
<div class="lb-trans"><p>Natera 是一家全球诊断公司，开发和商业化无细胞 DNA 及其他基因检测技术用于临床应用。该公司专注于三个主要领域：生殖健康（包括无创产前检测和携带者筛查）、肿瘤学（用于最小残留病和复发监测的肿瘤信息检测）以及器官移植（用于检测移植物损伤的无细胞 DNA 检测）。Natera 结合实验室检测、专有生物信息学和临床报告，为临床医生和患者提供个性化的基因信息。</p>
</div><p>Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.</p>
<div class="lb-trans"><p>主要产品包括 Panorama，一种无创产前检测，筛查胎儿染色体异常和特定单基因疾病；Horizon 携带者筛查，用于遗传性疾病；Signatera，一种个性化的肿瘤信息检测，用于检测癌症患者的最小残留病和监测治疗反应；以及 Prospera，一种供体来源的无细胞 DNA 检测，用于评估器官排斥的风险。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Natera</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Natera 更好的股票</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRSQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=NTRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Natera Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Natera 吗？</h2>
</div><p>Before you consider Natera, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Natera 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Natera 并不在名单上。</p>
</div><p>While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Natera 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

SWS Partners 购买了 Natera, Inc. $NTRA 的股票